Effect and adverse effect of direct acting antivirals for the patients with HCV

Effect and adverse effect of direct acting antivirals - Effect and adverse effect of direct acting antivirals

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044234

Enrollment

300

Registered

2021-05-18

Start date

2017-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis, type C, Liver cirrhosis, type C

Interventions

Administration of DAAs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. more than 20 years old 2. patient with genotype 1b HCV 3. over 50,000/ micro litter of platelet 4. the patient received curative HCC treatment (if experienced HCC) 5. the patient received explanation and consent 6. HCV RNA positive (if treatment naive patient)

Exclusion criteria

Exclusion criteria: 1. the female patient in pregnancy or breast-feeding 2. the patient experienced allergic reaction for daclatasvir and or asunaprevir 3. the liver cirrhosis patient with over Child-pugh score 7 4. the patient whose blood examination data was below the standard value 5. the patient the investigator judged unsuitable for study

Design outcomes

Primary

Measure	Time frame
sustained virological response	—

Countries

Japan

Contacts

Public ContactNaota Taura

Nagasaki university hospital Department of gastroenterology and hepatology

ntaura-g@nagasaki-u.ac.jp0958197481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026